Skip to main content

Advertisement

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms

Fig. 2

Functional selectivity of ZT55 characterized with cell proliferation and viability in cancer cells. (a) To determine the cell proliferation IC50 values, cells were treated for 48 h with various concentrations of ZT55 and their viability tested with CellTiter-Glo Assay. The mean IC50 results were calculated from three independent experiments. The error bars on bar graph denote mean ± SEM (n = 3). (b) Representative images were HEL cells under a phase contrast microscope after treating with ZT55 (0, 12.5, 25 or 50 μM) in 96-well plates for 24 h. Scale bar = 100 μm. (c) Analysis of HEL cells treated with certain concentrations of ZT55 at different time points (24, 48 and 72 h) were performed by CellTiter-Glo assay. The relative cell viability is shown as means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001)

Back to article page